FeesSafety
Pluang+

FibroBiologics expects initial safety data for diabetic foot ulcer therapy in Q4 2026, interim efficacy data in Q1 2027.

Company Fundamentals
16 Nov 2026, 23:13 WIB
PRNewsWire
View Source
Bullish
FibroBiologics expects initial safety data for diabetic foot ulcer therapy in Q4 2026, interim efficacy data in Q1 2027.

FibroBiologics reported progress in its Phase 1/2 trial of CYWC628, a fibroblast-based therapy for diabetic foot ulcers, with initial safety data expected in Q4 2026 and interim efficacy data in Q1 2027. The company increased its issued patents by 38% year-to-date and reduced operating expenses by 19%. Financially, it reported a net loss of $4 million for Q3 2026 but secured additional funding. These milestones highlight FibroBiologics' advancement in developing treatments for chronic diseases with unmet medical needs.

FibroBiologics' recent financial results and clinical progress provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 17, 2026 03:31 WIB: out of 150 priced US health-sector stocks, 31 rose and 118 fell. Notable movers include DNA (Ginkgo Bioworks Holdings Inc) down 11.55% at USD 8.50 with a typical hold time of 10 days, FLNA (Cassava Sciences Inc) up 10.56% at USD 0.47 with a typical hold time of 39 days and a buy order activity of 63%, and ALMS (Alumis Inc. Common Stock) down 10.09% at USD 5.04 with a typical hold time of 20 days and 100% sell order activity.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App